REQUEST A VISIT

As a registered member of Bavarian Nordic, you can request a visit from a Bavarian Nordic representative.

ENCEPUR ADULT is indicated for the active immunisation of people aged 12 years and over against tick-borne encephalitis (TBE).
ENCEPUR PAEDIATRIC  is indicated for the active immunisation of children aged 1-11 years against TBE.

View ENCEPUR SmPC

encepur

 

About ENCEPUR

ENCEPUR ADULTS (0.5 mL) and PAEDIATRIC (0.25 mL) is a suspension for injection in a pre-filed syringe, containing inactivated vaccine (TBE virus strain K23).

 

ENCEPUR  has protected individuals against TBE in the real world for 30 years

>30 million doses administered*

 

ENCEPUR offers flexible administration schedules to meet individual and family needs

Adult

Encepur Dosing Adults
Adults n = approximately 2,600 adolescents and adults

Children 

Encepur Dosing Children
 Children n = approximately 3,200 children

 

Long-lasting protection against TBE infection

Almost all (≥ 97%) of adolescents and adults showed protective antibody titres (NT ≥ 10) after primary course and 10 years after the first booster dose.

 

With over 30 million doses administered, Encepur offers long-lasting protection against TBE.

 

Safety

Safety of the Western TBE vaccines has been well established from numerous clinical studies.

 

The following side effects have been reported very commonly in randomised controlled trials.

Adults

Children

Headache

Headache in children aged 3 years and over

Myalgia

Sleepiness in children less than 3 years old

Injection site pain

Fever> 38ºC in children aged 1 to 2 years

Malaise

Injection site pain in children

 

The frequency category is defined as follows: very common ≥ 1/10 Flu-like symptoms (including hyperhidrosis, rigor, and fever) are particularly common after the first vaccination and generally resolve within 72 hours.

 

Contraindications

ENCEPUR should not be used in people who are known to be hypersensitive to the active substance, to any of the excipients or to any residues from manufacture such as formaldehyde, chlorotetracycline, gentamicin, neomycin, egg and chicken proteins.
 
People with acute illnesses requiring treatment should be vaccinated at the earliest 2 weeks after recovery.
 
Vaccination with a complication is a contraindication to repeated vaccination with the same vaccine until the cause is clarified.

Warnings and Precautions

Particular caution should be exercised vaccinating patients with pre-existing severe neurological conditions. The safe use of ENCEPUR cannot be proven for people who are sensitive to latex. Under no circumstances should the vaccine be injected intravascularly. Unintentional intravascular administration may provoke reactions, with shock in extreme cases. 

Please consult the SmPC for complete details. As is the case for all vaccines in general it is possible that not all vaccinated individuals will develop protective immunity against TBE.

In normal cases there is no increased risk in vaccination with Encepur for subjects classified with “allergy to chicken protein” based solely on a questionnaire or positive prick test. Vaccination with Encepur normally entails no increased risk for such individuals. 

Encepur-Family

Our Commitment to Raising Awareness of TBE Prophylaxis to Protect Public Health 

Partnering with healthcare professionals to: 

Image
warning

Help raise awareness of the growing risk of TBE

Image
Vaccine

Educate about the importance of prevention through vaccination

Image
consistency

Ensure a consistent, reliable product supply chain​​

Raising awareness and taking action together to help lower the risk of TBE to your patients
 
*ENCEPUR refers to ENCEPUR PAEDIATRIC and ENCEPUR ADULT